AlgiPharma AS

10 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Oct 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 1, 2027
The maintenance fee for Use of alginate oligomers as blood anticoagulants (US 11,712,448) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
1 fee due Oct 21, 2027
The maintenance fee for Use of alginate oligomers in combating biofilms (US 10,624,920) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 9,877,983	Use of alginate oligomers in combating biofilms In force Ends no later than Oct 24, 2028 · From the USPTO record	In force	Ends no later than Oct 24, 2028	From the USPTO record
US 10,624,920	Use of alginate oligomers in combating biofilms In force Ends no later than Oct 24, 2028 · From the USPTO record	In force	Ends no later than Oct 24, 2028	From the USPTO record
US 8,680,072	Use of alginate oligomers in combating biofilms In force Term ends Mar 1, 2030 · From the USPTO record	In force	Term ends Mar 1, 2030	From the USPTO record
US 8,815,831	Treatment of Acinetobacter with alginate oligomers and antibiotics In force Ends no later than Jun 3, 2030 · From the USPTO record	In force	Ends no later than Jun 3, 2030	From the USPTO record
US 9,801,901	Alginate oligomers for use in overcoming multidrug resistance in bacteria In force Term ends Aug 31, 2030 · From the USPTO record	In force	Term ends Aug 31, 2030	From the USPTO record
US 9,018,158	Alginate oligomers for use in overcoming multidrug resistance in bacteria In force Term ends Dec 4, 2030 · From the USPTO record	In force	Term ends Dec 4, 2030	From the USPTO record
US 11,712,448	Use of alginate oligomers as blood anticoagulants In force Term ends Dec 19, 2034 · From the USPTO record	In force	Term ends Dec 19, 2034	From the USPTO record
US 11,992,553	Inhalable Powder Formulations of Alginate Oligomers In force Term ends Jun 6, 2036 · High confidence	In force	Term ends Jun 6, 2036	High confidence
US 11,413,306	Alginate Oligomers for the Treatment or Prevention of Microbial Overgrowth in the Intestinal Tract In force Term ends Oct 6, 2036 · High confidence	In force	Term ends Oct 6, 2036	High confidence
US 12,649,000	Use of Alginate Oligomers to Enhance the Translocation of Micro/Nanoparticles Across Mucus Layers In force Term ends Feb 1, 2042 · High confidence	In force	Term ends Feb 1, 2042	High confidence

Also on record, not counted in the 10: 2 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 4 no status recorded

List them